ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CERT Certara Inc

17.67
1.51 (9.34%)
Apr 23 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 499,655
Bid Price 16.38
Ask Price 17.66
News -
Day High 16.91

Low
11.81

52 Week Range

High
24.70

Day Low 16.19
Company Name Stock Ticker Symbol Market Type
Certara Inc CERT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.51 9.34% 17.67 20:00:00
Open Price Low Price High Price Close Price Prev Close
16.19 16.19 16.91 16.73 16.16
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,717 499,655 $ 16.63 $ 8,308,186 - 11.81 - 24.70
Last Trade Time Type Quantity Stock Price Currency
18:43:32 formt 139 $ 17.67 USD

Certara Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.67B 159.86M - 354.34M -55.36M -0.35 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Certara News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CERT Message Board. Create One! See More Posts on CERT Message Board See More Message Board Posts

Historical CERT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week17.4017.4015.7816.35461,1060.271.55%
1 Month16.8219.179215.7817.43550,6770.855.05%
3 Months16.4219.870215.7817.63536,7571.257.61%
6 Months13.3919.870211.8116.19588,6344.2831.96%
1 Year24.5024.7011.8117.41764,345-6.83-27.88%
3 Years29.9545.4810.6021.88804,789-12.28-41.00%
5 Years35.0145.4810.6022.88795,538-17.34-49.53%

Certara Description

Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA and other regions, of which a majority of revenue is derived from the United States.

Your Recent History

Delayed Upgrade Clock